Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHF 5633 vs Poractant Alfa in Preterm Neonates with RDS
NCT02452476Phase 2Completed
- Sponsor
- Chiesi Farmaceutici S.p.A.
- Start
- Jan 2016
- Primary completion
- May 2018
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
A Phase 2 trial of CHF 5633 in respiratory distress syndrome (RDS), sponsored by Chiesi Farmaceutici S.p.A.. Started Jan 2016; status: completed.
02
Drugs
CHF 5633
03
Conditions
respiratory distress syndrome (RDS)
Beyond the preview
Go deeper on NCT02452476.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02452476.